Opko Health Inc (OPK) : The consensus price target for Opko Health Inc (OPK) is $15.33 for the short term with a standard deviation of $5.03. The most optimist securities analyst among the 3 who monitor the stock believes that the stock can reach $20, however, the pessimist price target for the company is $10.
Opko Health Inc (OPK) : The consensus on Opko Health Inc (OPK) based on 4 analyst recommendation on the company stock is 2, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Also, In the latest statement by the brokerage house, Deutsche Bank maintains its outlook on Opko Health Inc (NYSE:OPK). The current rating of the shares is Hold, according to the research report released by the firm. The brokerage firm lowers the price target from $11 per share to $10 per share. The rating by the firm was issued on June 16, 2016.
Opko Health Inc (NYSE:OPK): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $9.31 and $9.19 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $9.54. The buying momentum continued till the end and the stock did not give up its gains. It closed at $9.29, notching a gain of 2.09% for the day. The total traded volume was 3,515,257 . The stock had closed at $9.10 on the previous day.
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.